Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	206184-49-8
Formula :	C₉H₁₆N₅O₅P
M.W :	305.23
SMILES Code :	NC1=NC=NC2=C1N=CN2C[C@H](OCP(O)(O)=O)C.[H]O[H]
Synonyms :	PMPA hydrate; GS 1278 hydrate
MDL No. :	MFCD11519982
InChI Key :	PINIEAOMWQJGBW-FYZOBXCZSA-N
Pubchem ID :	21146529

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H332-H335
Precautionary Statements:	P280-P305+P351+P338-P310

MΦ cells	5-600 µg/mL	5 days	Evaluate the cell viability of Tenofovir, AuNPs, and AuNP-TNF in MΦ cells, showing that the viability of AuNP-TNF-treated cells was significantly higher than those treated with free TNF.	PMC9850711
PBMCs	5-600 µg/mL	5 days	Evaluate the cell viability of Tenofovir, AuNPs, and AuNP-TNF in PBMCs, showing that the viability of AuNP-TNF-treated cells was significantly higher than those treated with free TNF.	PMC9850711
TZM-bl cells	5-600 µg/mL	48 h	Evaluate the cell viability of Tenofovir, AuNPs, and AuNP-TNF in TZM-bl cells, showing that the viability of AuNP-TNF-treated cells was significantly higher than those treated with free TNF.	PMC9850711
CD4+ T cells	10 μM	12 h	To stop ongoing HIV-1 infection, the results showed that Tenofovir effectively suppressed viral replication.	PMC10907297
MΦ cells	5-600 µg/mL	5 days	Assess cell viability, results showed that AuNP-TNF had significantly higher cell viability than free TNF.	PMC9850711
PBMCs	5-600 µg/mL	5 days	Assess cell viability, results showed that AuNP-TNF had significantly higher cell viability than free TNF.	PMC9850711
TZM-bl cells	5-600 µg/mL	48 h	Assess cell viability, results showed that AuNP-TNF had significantly higher cell viability than free TNF.	PMC9850711
NL4.3-ΔNef-eGFP infected CD4+ T cells	10 μM	12 h	To inhibit viral replication and prevent ongoing infection. The results showed that Tenofovir successfully inhibited viral replication, and no ongoing infection was observed in the experiment.	PMC10907297
CD4+ T cells	10 μM	18 h	To inhibit viral replication and prevent viral persistence in cells. The results showed that Tenofovir successfully inhibited viral replication, and no ongoing infection was observed in the experiment.	PMC10907297

Mice	MISTRG-6-15 mouse model	Oral	1 g/kg	Not specified	Suppress HIV-1 replication	PMC9753998
BALB/c mice	Healthy mice	Intravenous injection	5 mg/kg	Single injection, observed for 7 days	Evaluate the biodistribution of Cy5.5-AuNPs in BALB/c mice, showing that Cy5.5-AuNPs mainly accumulated in the liver and lungs, and gradually decreased within 7 days.	PMC9850711
Mice	Chronic unpredictable mild stress (CUMS) model	Gastric administration	30 mg/kg	Once daily for 2 weeks	Tenofovir significantly reversed the chronic stress-induced negative emotional behaviors, including increased center time% in the open field test, increased open arms time% and open arms entries% in the elevated plus maze test, increased recognition index in the novel object recognition test, increased sucrose preference% in the sucrose preference test, and decreased immobility time% in both the forced swimming and tail suspension tests.	PMC9933381
Mice	BLT humanized mouse model	Oral	1560 mg/kg	Once daily for five weeks	Tenofovir was used to suppress HIV infection, and ART successfully suppressed the virus to below the limit of detection	PMC9975043
Mice	Pregnant mice	Oral gavage	100 mg/kg	Once daily for 5 days	Tenofovir treatment reduced red blood cell counts, bone marrow cellularity, splenic HSCs, and erythroid progenitor numbers in pregnant mice, and decreased HSC division rates.	PMC11709122
Mice	HIV infection model	Oral	5.35mg	Once daily for 42 days	To evaluate the effect of antiretroviral therapy on HIV-infected mice	PMC9732419
Rhesus macaques	SIV infection model	Intravenous infusion	0.1 mg/kg	Weekly for 3 or 10 weeks	To evaluate the latency reversal effect of AZD5582 in SIV-infected rhesus macaques, results showed that AZD5582 induced SIV-RNA expression.	PMC7111210
Hu-NSG-Tg (IL-15) mice	HIV infection model	Intraperitoneal injection	500 µg/mouse	Twice a week for 2 weeks	To evaluate the antiviral effect of Bi-Ab32/16 in an HIV-infected mouse model. Results showed that Bi-Ab32/16 treatment led to a significant decline in NK cell numbers and was negatively correlated with the time to viral rebound, indicating potential adverse effects on NK cell dynamics.	PMC11829058
Mice	HIV-1 infection model	Oral	1,560 mg/kg	Daily until the end of the study	To suppress HIV-1 replication, the results showed that Tenofovir effectively reduced viral load.	PMC10907297
Mice	BLT mouse model	Oral	80 mg/kg	Daily	Evaluate the antiviral efficacy of Tenofovir in HIV-infected mice	PMC11163220
Mice	HIV-1 infection model	Oral	90 mg/kg	Daily for 7 weeks	Suppress HIV-1 viral replication	PMC10518630
Mice	Chronic unpredictable mild stress (CUMS) model	Gastric administration	30 mg/kg	Once daily for 2 weeks	Tenofovir significantly reversed chronic stress-induced negative emotional behaviors, including reduced anxiety- and depressive-like behaviors, and improved microglial morphological activation and biological immuno-inflammation.	PMC9933381
NSG mice	BLT humanized mouse model	Oral	1,560mg/kg	Continuous administration	Evaluate the impact of Gal-9 on HIV persistence	PMC9975043
Mice	Pregnant and non-pregnant mice	Oral gavage	100 mg/kg	Daily for 5 days	In non-pregnant female mice, reverse transcriptase inhibitors had little or no effect on blood cell counts, or bone marrow or spleen hematopoiesis. In pregnant mice, reverse transcriptase inhibitors reduced red blood cell counts, bone marrow cellularity and the frequency of HSCs and LSK cells in the spleen. The absolute number of CD71+Ter119+ erythroid progenitors declined in the spleens of pregnant mice treated with reverse transcriptase inhibitors.	PMC11709122
Humanized DRAGA mice	HIV infection model	Oral	5.35mg	Once daily for 42 days	Evaluate the therapeutic effect of antiretroviral therapy on HIV infection	PMC9732419
Hu-NSG-Tg (IL-15) mice	HIV infection model	Oral	131 mg/kg	From 6 to 9 weeks post-infection (WPI)	To evaluate the therapeutic effect of Tenofovir in an HIV infection model	PMC11829058
Mice	HIV infection model	Oral	80 mg/kg	Continuous administration	Suppression of HIV replication	PMC11163220
NSG mice	Humanized mouse model of HIV-1 infection	Oral	90 mg/kg	Once daily for seven weeks	Suppress HIV-1 viral replication	PMC10518630

{[proInfo.proName]}

CAS No.: 206184-49-8

{[proInfo.proName]}

CAS No.: 206184-49-8

Alternative Products

Product Details of Tenofovir hydrate

Safety of Tenofovir hydrate

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT01475851	Hepatitis B, Chronic	Phase 3	Completed	-	Japan ... More >> GSK Investigational Site Aichi, Japan, 466-8560 GSK Investigational Site Aichi, Japan, 467-8602 GSK Investigational Site Chiba, Japan, 260-8677 GSK Investigational Site Fukuoka, Japan, 803-8505 GSK Investigational Site Hiroshima, Japan, 734-8551 GSK Investigational Site Hokkaido, Japan, 060-0033 GSK Investigational Site Kagoshima, Japan, 890-8520 GSK Investigational Site Kanagawa, Japan, 213-8587 GSK Investigational Site Miyagi, Japan, 980-8574 GSK Investigational Site Tokyo, Japan, 105-8470 GSK Investigational Site Tokyo, Japan, 180-8610 Less <<
NCT01475851	-		Completed	-	-
NCT01480284	-		Completed	-	-
NCT01480284	Hepatitis B, Chronic	Phase 3	Completed	-	Japan ... More >> GSK Investigational Site Aichi, Japan, 466-8560 GSK Investigational Site Aichi, Japan, 467-8602 GSK Investigational Site Chiba, Japan, 260-8677 GSK Investigational Site Fukui, Japan, 918-8503 GSK Investigational Site Fukuoka, Japan, 803-8505 GSK Investigational Site Fukuoka, Japan, 810-8539 GSK Investigational Site Fukuoka, Japan, 812-8582 GSK Investigational Site Fukuoka, Japan, 820-8505 GSK Investigational Site Gifu, Japan, 500-8717 GSK Investigational Site Hiroshima, Japan, 734-8530 GSK Investigational Site Hyogo, Japan, 651-2273 GSK Investigational Site Hyogo, Japan, 663-8501 GSK Investigational Site Kagawa, Japan, 760-8557 GSK Investigational Site Kagoshima, Japan, 890-8520 GSK Investigational Site Kagoshima, Japan, 892-8512 GSK Investigational Site Kanagawa, Japan, 213-8587 GSK Investigational Site Kumamoto, Japan, 862-8655 GSK Investigational Site Miyagi, Japan, 980-8574 GSK Investigational Site Miyazaki, Japan, 880-0003 GSK Investigational Site Nagasaki, Japan, 852-8501 GSK Investigational Site Nagasaki, Japan, 856-8562 GSK Investigational Site Nara, Japan, 630-8305 GSK Investigational Site Okayama, Japan, 700-0913 GSK Investigational Site Okayama, Japan, 700-8511 GSK Investigational Site Osaka, Japan, 540-0006 GSK Investigational Site Osaka, Japan, 564-0013 GSK Investigational Site Saga, Japan, 840-8571 GSK Investigational Site Tokyo, Japan, 105-8470 GSK Investigational Site Tokyo, Japan, 105-8471 GSK Investigational Site Tokyo, Japan, 140-8522 GSK Investigational Site Tokyo, Japan, 162-8655 GSK Investigational Site Tokyo, Japan, 180-8610 Less <<

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed